Pakistan on Friday announced its annual budget for financial year 2020-21, setting ambitious targets of 2.1 per cent GDP growth, a 7 per cent fiscal deficit and an increase in tax revenues, even as it reels from a surge in novel coronavirus cases.
The GDP target is much higher than a recent World Bank projection that Pakistan will have another year of negative growth at -0.2 per cent, while the fiscal deficit is much lower than the 9.4 per cent it is expected to hit in the current year.
Headline inflation that hit a decade-high of 14.56 per cent in January is estimated at an average rate 6.5 per cent in the next year.
Economic analysts termed the targets unrealistic, forecasting that the government will need to introduce a mid-year supplementary budget given the economic disruptions caused by the pandemic.
"It looks unlikely that they will meet the fiscal deficit target," said Saad Hashemy, Executive Director at BMA Capital.
Total expenditure for the next fiscal year will be 7.136 trillion Pakistani rupees ($43.45 billion), said Minister for Industries and Production Hammad Azhar as he introduced the budget in a rowdy session of parliament.
Only 25 per cent of members were in attendance in an attempt to ensure social distancing.
"Corona is a flu!" shouted one opposition member, taking a jibe at prime minister Imran Khan, who in his initial response to COVID-19 had played down the respiratory disease.
Pakistan has struggled to contain the virus and the World Health Organization has warned that the acceleration of infections could overwhelm the under-funded healthcare system.
Official statistics showed a record 6,397 new cases and 107 deaths on Thursday, taking the tally to 125,933 cases and 2,463 fatalities.
Azhar said in his speech that the outbreak has caused Pakistan's nearly $300 billion economy a loss of 3.3 trillion Pakistani rupees ($20.09 billion).
"The long lockdown, a countrywide shutdown of business, travel restrictions and social distancing have diminished economic activities, which have had a negative impact on growth rate and investment," Azhar added.
On the expenditure side, debt servicing will take up 2.946 trillion Pakistani rupees ($17.94 billion) - 41 per cent of the country's spending.
The next largest spending head, 18 per cent of expenditures, will be on defence, for which 1.29 trillion Pakistani rupees ($7.85 billion) have been allocated. Defence spending is up 12 per cent from last year's allocation despite Pakistan's financial crunch.
Little is left to spend in other areas, and even the current expenditure of running the government requires local and international borrowing.
Pakistan plans to collect 4.96 trillion Pakistani rupees ($30.22 billion) in tax through its revenue board - which is around a trillion rupees, or 25 per cent, more than the last year's collection.
"We believe the tax collection target looks highly over optimistic in prevailing economic conditions," said analyst Mohammed Sohail of Topline Securities.
To plug the spending and revenue gap, Pakistan will look to access $2.2 trillion Pakistani rupees ($13.5 billion) in gross external finances, including loans, aid and grants - much of which will be used for repayment of outstanding external credit.
Pakistan last year entered a three-year, $6 billion IMF bailout programme.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.